Clinical Trial Update: BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006) [Phase 1]

View source ↗

Summary

This Phase 1 study evaluated BOLD fMRI and cerebral blood flow as biomarkers for cognition-enhancing drug candidates in dementia. The study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia

Drugs mentioned

• Investigational cognition-enhancing drug candidate

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Dementia | Phase 1 | Status: COMPLETED